New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:13 EDTINFIInfinity sees reporting data from both wholly owned clinical programs in 1H13
In the first half of 2013, Infinity expects to report data from both of its wholly owned clinical programs, phosphoinositide-3-kinase and heat shock protein 90, that will inform potential paths to registration. Each program targets areas of unmet patient need such as advanced hematologic malignancies, inflammatory diseases and non-small cell lung cancer. Infinity also announced its second potent, oral PI3K-delta,gamma inhibitor, IPI-443. Nonclinical studies of IPI-443 are now under way, which are designed to enable the initiation of Phase 1 clinical development. Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride, a potent and selective Hsp90 inhibitor.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:52 EDTINFIInforma Business Information to hold a conference
Subscribe for More Information
November 6, 2014
18:00 EDTINFIInfinity Pharmaceuticals sees FY14 loss $20M-$30M
Infinity Pharmaceuticals had seen FY14 loss at $170M-$180M.
16:09 EDTINFIInfinity Pharmaceuticals sees FY14 revenue $160M-$170M, consensus $127.78M
Subscribe for More Information
16:08 EDTINFIInfinity Pharmaceuticals reports Q3 EPS $2.03,may not compare to consensus (86c)
Subscribe for More Information
09:09 EDTINFIInfinity announces presentation of new duvelisib preclinical data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use